BioSpace News Archive

Dovetail Genomics, the world-leader in high-quality de novo genome assembly, and Revive & Restore, the leading wildlife conservation organization promoting the incorporation of biotechnologies into standard conservation practice, announced the second project in the “A Genome for…” program, sequencing a female wolverine nicknamed Laura.

NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that it has appointed William Hodder as CEO.

Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) announces that it will release its financial results for the third quarter 2021 after the market closes on Wednesday, October 27, 2021.

Transcat, Inc. announced that it will release its second quarter fiscal year 2022 results after the close of financial markets on Tuesday, November 2, 2021.

Dr. Elazar Rabbani to remain Chairperson of the Board and will assume new role as Chief Scientific Officer

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis.

Bone Biologics Corp. today announced that it closed a public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Neurelis, Inc., announced today that it has made the following additions to its leadership team:

Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced installation of its Genesis Robotic Magnetic Navigation system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment of cardiac arrhythmias.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), today announced that it has expanded its ongoing Phase 1b/2 trial of BXCL701, the Company’s investigational, orally administered innate immune activator, in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients with either de novo or treatment-emergent small-cell neuroendocrine carcinoma (SCNC).